4278-08-4

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Fluoro-phenyl)-1H-imidazole is used as a chemical intermediate for the synthesis of various pharmaceutical drugs. The presence of the fluorine atom and the imidazole ring structure can contribute to the compound's reactivity and biological activity, making it a valuable component in the development of new medications.
Used in Medicinal Chemistry Research:
2-(4-Fluoro-phenyl)-1H-imidazole is used as a research compound in the field of medicinal chemistry. Its unique structure and properties can be further explored and modified to investigate its potential applications in drug discovery and development, as well as to understand its interactions with biological targets.
Used in Chemical Synthesis:
2-(4-Fluoro-phenyl)-1H-imidazole is used as a building block in the synthesis of more complex organic compounds. Its reactivity and the presence of the fluorine atom can be exploited to create new molecules with desired properties, such as improved stability, solubility, or biological activity.
Note: The specific uses of 2-(4-Fluoro-phenyl)-1H-imidazole may vary depending on the context and the requirements of the application. Further research and development may be necessary to fully understand its potential and to optimize its use in various industries.

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 165901-26-8 2-(4-fluorophenyl)-4,5-dihydro-1H-imidazole 

Downstream Products

• 72542-80-4 5-(4-fluoro-phenyl)-[1,2,4]oxadiazole-3-carboxylic acid 
• 670-96-2 2-Phenylimidazole 
• 1431659-41-4 C₂₂H₂₃FN₆O₂ 
• 1313519-30-0 (R)-7-ethyl-2-(2-(4-fluorophenyl)-1H-imidazol-1-yl)-5-methyl-8-(oxetan-3-yl)-7,8-dihydropteridin-6(5H)-one 
• 1313523-60-2 C₂₁H₂₃FN₆O 
• 1313523-58-8 C₂₂H₂₃FN₆O 
• 1313523-55-5 C₂₂H₂₂F₄N₆O 
• 1313522-44-9 C₂₁H₁₇F₇N₆O 
• 1431659-52-7 C₂₂H₂₁FN₈O 
• 1313519-83-3 C₂₂H₂₁FN₈O 
• 1313519-64-0 (R)-7-ethyl-2-(2-(4-fluorophenyl)-1H-imidazol-1-yl)-5-methyl-8-(1-methyl-1H-pyrazol-4-yl)-7,8-dihydropteridin-6(5H)-one 

Relevant academic research and scientific papers

New Insights into the Role of Imidazolium-Based Promoters for the Electroreduction of CO2 on a Silver Electrode

The electrochemical reduction of CO2 to CO is a reaction of central importance for sustainable energy conversion and storage. Herein, structure-activity relationships of a series of imidazolium-based cocatalysts for this reaction are described,

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.

Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents

A series of 2-aryl-4-benzoyl-imidazoles (ABI) was synthesized as a result of structural modifications based on the previous set of 2-aryl-imidazole-4- carboxylic amide (AICA) derivatives and 4-substituted methoxylbenzoyl-aryl- thiazoles (SMART). The average IC50 of the most active compound (5da) was 15.7 nM. ABI analogues have substantially improved aqueous solubility (48.9 μg/mL for 5ga vs 0.909 μg/mL for SMART-1, 0.137 μg/mL for paclitaxel, and 1.04 μg/mL for combretastatin A4). Mechanism of action studies indicate that the anticancer activity of ABI analogues is through inhibition of tubulin polymerization by interacting with the colchicine binding site. Unlike paclitaxel and colchicine, the ABI compounds were equally potent against multidrug resistant cancer cells and the sensitive parental melanoma cancer cells. In vivo results indicated that 5cb was more effective than DTIC in inhibiting melanoma xenograph tumor growth. Our results suggest that the novel ABI compounds may be developed to effectively treat drug-resistant tumors.

1H-IMIDAZOLE PREPARATION VIA PERMANGANATE DEHYDROGENATION OF 2-IMIDAZOLINES

Permanganate and manganate ions were evaluated as dehydrogenating agents in the conversion of 2-substituted 2-imidazolines into the corresponding 2-substituted imidazoles.It was found that permanganate ion in dry dioxane efficiently performs this transformation rendering this method competitive with related procedures.